Braizon Therapeutics, Inc. / Japan
台灣醫療科技展展位:
We are a CNS drug-delivery focused startup headquartered in Tokyo, Japan. Braizon's main product is Brain Access, an engineered polymer nanoparticle targeted to cross the blood brain barrier and deliver drugs within the brain parenchyma. The first version of this platform is focused on oligonucleotide and small molecule drugs.
With very high loading efficiency and drug carrying capacity, Brain Access offers a cost effective solution to the blood brain barrier problem, enabling reformulated and novel drugs to treat diseases of the CNS.
 
成立時間2015
資本額USD 10
員工數13
產品/服務類別
基因醫學 生技製藥
採購與合作需求項目
Novel drug seeds for neurological indications, particularly those with poor uptake from systemic circulation but strong efficacy data.
供應與銷售項目
A solution to formulate drugs for targeted delivery into the brain from IV administration, with preclinical development support
最新商機情報
你可能有興趣的產品服務
你可能有興趣的機構/企業
© Institute for Biotechnology and Medicine Industry & Research Center for Biotechnology and Medicine Policy
聯絡我們
Loading...